Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.467

+3.3%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: LJM	12/13/2006 5:59:08 PM
	Read Replies (1) of 66

Valeant Pharmaceuticals And Metabasis Therapeutics License Rights To Hepatitis B Compound Pradefovir To Schering-Plough Corp>MBRX Dec 13, 2006 17:01:00 (ET) DOW JONES NEWSWIRES Valeant Pharmaceuticals International (VRX) and Metabasis Therapeutics Inc. (MBRX) agreed to assign and license development and commercial rights to pradefovir to Schering-Plough Corp. (SGP), the companies said after Wednesday's closing bell. Under the agreement, Schering-Plough will make an upfront payment of $19.2 million to Valeant and $1.8 million to Metabasis, and will pay up to $90 million in additional fees to both companies upon the achievement of certain development and regulatory goals, Valeant said. Valeant would receive about $65 million of the additional fees, while Metabasis would get $25 million. Schering-Plough will also pay royalties to Valeant and Metabasis if pradefovir is commercialized and will be responsible for all forward research and development activities, Schering-Plough said. Valeant licensed pradefovir from Metabasis in 2000 and has been conducting clinical trials for its use to treat compensated chronic hepatitis B. Pradefovir is a compound that uses Metabasis' technology to enable higher concentrations of the drug in the liver, the primary site of replication for the hepatitis B virus. The deal is expected to close in the first quarter. -Ana Campoy; 415-439-6400; AskNewswires@dowjones.com (END) Dow Jones Newswires December 13, 2006 16:58 ET (21:58 GMT)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next